Clostridium difficile infection: managing the risks.
Northern Arizona Healthcare, Flagstaff, USA.
Larissa
L
DeDea
D016360:Clostridioides difficile / Q000472:pathogenicity*; D003015:Clostridium Infections / Q000453:epidemiology* / Q000382:microbiology; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology* / Q000382:microbiology; D005744:Gastric Acid / Q000502:physiology*; D006635:Histamine H2 Antagonists; D006801:Humans; D006863:Hydrogen-Ion Concentration; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012306:Risk; D013270:Stomach / Q000737:chemistry*
D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors